Sequencing study on familial lung squamous cancer

Oncology Letters

Volumn 10, Issue 4, 2015, Pages 2634-2638

  Li, Shaomin ^a   Wang, Lina ^a   Ma, Zhenchuan ^a   Ma, Yuefeng ^a   Zhao, Jiangman ^b   Peng, Bo ^b   Qiao, Zhe ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b Zhangjiang Center for Translational Medicine   (China)

Author keywords

Familial lung squamous cancer; Mutation; Whole exome sequencing

Indexed keywords

CISPLATIN; CLATHRIN HEAVY CHAIN; NAVELBINE; PHOSPHODIESTERASE IV;

AGED; ARTICLE; CASE REPORT; GENE MUTATION; GENE SEQUENCE; HISTOLOGY; HUMAN; HUMAN TISSUE; LOBECTOMY; MALE; MULTIPLE CYCLE TREATMENT; PEDIGREE ANALYSIS; SQUAMOUS CELL LUNG CARCINOMA; VALIDATION PROCESS;

EID: 84940047543     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3583     Document Type: Article

References (25)

1. World Health Organization GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Default.aspx. Accessed October 10, 2014.
2. Suh JH: Current readings: Pathology, prognosis, and lung cancer. Semin Thorac Cardiovasc Surg 25: 14-21, 2013.
3. Detterbeck FC, Postmus PE and Tanoue LT: The stage classification of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143 (Suppl): e191S-e210S, 2013.
4. Van Schil PE, Sihoe AD and Travis WD: Pathologic classification of adenocarcinoma of lung. J Surg Oncol 108: 320-326, 2013.
5. Kris MG, Johnson BE, Kwiatkowski DJ, et al: Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's lung cancer mutation consortium (LCMC). J Clin Oncol 29: CRA7506, 2011.
6. Palmer JD, Zaorsky NG, Witek M and Lu B: Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancer. J Thorac Dis 6: 387-398, 2014.
7. Ulivi P, Zoli W, Capelli L, Chiadini E, Calistri D and Amadori D: Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation. Mol Clin Oncol 1: 575-581, 2013.
8. Oxnard GR, Binder A and Jänne PA: New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 31: 1097-1104, 2013.
9. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C and Micklem G: Identification of the breast cancer susceptibility gene BRCA2. Nature 378: 789-792, 1995.
10. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994.
11. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M and Kolodner R: The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75: 1027-1038, 1993.
12. Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, et al: Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature 368: 258-261, 1994.
13. van Noesel J, van der Ven WH, van Os TA, Kunst PW, Weegenaar J, Reinten RJ, Kancha RK, Duyster J and van Noesel CJ: Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation. J Clin Oncol 31: e161-e164, 2013.
14. Ohtsuka K, Ohnishi H, Kurai D, Matsushima S, Morishita Y, Shinonaga M, Goto H and Watanabe T: Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation. J Clin Oncol 29: e191-e192, 2011.
15. Yamamoto H, Higasa K, Sakaguchi M, Shien K, Soh J, Ichimura K, Furukawa M, Hashida S, Tsukuda K, Takigawa N, et al: Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst 106: djt338, 2014.
16. Li H and Durbin R: Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26: 589-595, 2010.
17. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, and DePristo MA: The genome analysis toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 20: 1297-1303, 2010.
18. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al: A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet 43: 491-498, 2011.
19. Ettinger DS, Akerley W, Bepler G, et al; NCCN Non-Small Cell Lung Cancer Panel Members: Non-small cell lung cancer. J Natl Compr Canc Netw 8: 740-801, 2010.
20. Forbes SA, Bindal N, Bamford S, et al: COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 39: 945-950, 2011.
21. Wong KA, Wilson J, Russo A, et al: Intersectin (ITSN) family of scaffolds function as molecular hubs in protein interaction networks. PLoS One 7: e36023, 2012.
22. Vinayagam A, Stelzl U, Foulle R, et al: A directed protein interaction network for investigating intracellular signal transduction. Sci Signal 4: rs8, 2011.
23. DeWan AT, Egan KB, Hellenbrand K, Sorrentino K, Pizzoferrato N, Walsh KM and Bracken MB: Whole-exome sequencing of a pedigree segregating asthma. BMC Med Genet 13: 95, 2012.
24. Liu SH, Towler MC, Chen E, Chen CY, Song W, Apodaca G and Brodsky FM: A novel clathrin homolog that co-distributes with cytoskeletal components functions in the trans-Golgi network. EMBO J 20: 272-284, 2001.
25. Sens-Abuázar C, Napolitano E, Ferreira E, Osório CA, Krepischi AC, Ricca TI, Castro NP, da Cunha IW, Maciel Mdo S, Rosenberg C and Brentani MM: Down-regulation of ANAPC13 and CLTCL1: Early events in the progression of preinvasive ductal carcinoma of the breast. Transl Oncol 5: 113-123, 2012.